CM Life Sciences III in an 8-K filed today said its shareholders voted in favor of the business combination with pharmaceutical company EQRx. About 92 percent of the Class A shares voted were cast in support of the merger.
While the filing did not mention any redemption numbers, the SPAC has traded below $10 since Aug. 9, within days after the deal was announced.
As originally presented, the deal included approximately $552 million of cash held in the SPAC’s trust (assuming no redemptions), and a fully committed PIPE of $1.2 billion from healthcare investors led by SB Northstar. Read more.
